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The toll of heart failure, in terms of hospital admissions,
clinical events, and spiraling health care costs, continues
unabated in the United States. Recent trends afﬁrm that the
number of patients hospitalized with heart failure has grown
steadily over the past 30 years, and with aging of the U.S.
population, this trend will undoubtedly continue (1–3).
Heart failure remains the leading cause of hospitalization in
individuals over 65 years of age. Despite evidence-based
guidelines, performance measures, quality improvement pro-
grams, and public reporting of hospital-level performance
data, the number of patients dying or readmitted to hospitals
in the year after hospital discharge remains excessive (4–6)
and is equivalent in patients with depressed and those with
preserved left ventricular (LV) systolic function (7).See page 123Performance measures developed by the American
College of Cardiology and American Heart Association in
collaboration with the Physician Consortium for Perfor-
mance Improvement (8) and those implemented and pub-
licly reported by the Joint Commission and the Center for
Medicare and Medicaid Services (9,10) are intended to
improve utilization of evidence-based therapies that have
been proven effective in randomized clinical trials and in-
corporated into practice guidelines (11). However, adher-
ence to these process measures at the hospital level has not
translated into improved clinical outcomes after hospital
discharge in several analyses, which has been the source of
considerable concern and controversy (5,12,13).
The report from the ARIC (Atherosclerosis Risk In
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failure quality in several important directions. Blecker et al.
(14) address processes of care and outcomes in 4,345 patients
with heart failure who were hospitalized in the ARIC study
in 2005 through 2009, and they report signiﬁcant differences
in adherence to evidence-based diagnosis and treatment
strategies in those with a principal versus a secondary diag-
nosis of heart failure. The results represent a reality check
with several salient potential policy implications.
First, heart failure quality measures publicly reported by
the Joint Commission and the Center for Medicare and
Medicaid Services (9,10) and endorsed by the American
College of Cardiology and American Heart Association in
collaboration with the Physician Consortium for Perfor-
mance Improvement (8) pertain only to patients with a
principal diagnosis of heart failure. However, previous studies
indicate that there are signiﬁcantly more patients hospitalized
in the United States with a secondary diagnosis than with
a primary diagnosis of heart failure, affecting millions of
patients annually (15,16), a ﬁnding that is conﬁrmed in the
current study in which over 60% of hospitalizations in
patients with heart failure carried a secondary rather than
a primary heart failure diagnosis (14). The current data
demonstrate that adherence to heart failure quality measures
is signiﬁcantly less rigorous among patients with a secondary
diagnosis of heart failure, with fewer undergoing diagnostic
testing to assess LV function and fewer with LV sys-
tolic dysfunction discharged on an angiotensin-converting
enzyme (ACE) inhibitor or angiotensin receptor blocker
(ARB).Whether the diagnosis of heart failure was primary or
secondary, the lack of either assessment of LV function or
appropriate use of ACE inhibitors/ARBs was associated with
signiﬁcantly higher post-discharge mortality rates at 1 year.
Thus, there is evidence of an important gap in care affecting
a large number of heart failure patients who are currently
under the radar screen of public scrutiny, and hence there is
an opportunity for substantial quality improvement. Future
iterations of performance measures will need to take this gap
in care into account.
The second important ﬁnding in the study of Blecker
et al. (14) is the highly signiﬁcant association between
process measures and outcomes. The connection between
LV function assessment or the appropriate use of ACE
inhibitors/ARBs in those with LV systolic dysfunction and
post-hospitalization mortality has been an elusive ﬁnding in
previous analyses (5,12,13), although highly signiﬁcant in
the outpatient setting (17). The real-world observations in
the current ARIC study hospitalization data (14), indicating
signiﬁcant relations between assessment of LV function
(odds ratio: 0.66) and treatment of ACE inhibitors/ARBs
for LV systolic dysfunction (odds ratio: 0.72) and 1-year
mortality, are a strong vindication of these inpatient process
measures. These associations with mortality were signiﬁcant
whether the diagnosis of heart failure was the principal or
a secondary reason for hospitalization. Similar association
of beta-blocker therapy in patients with LV systolic
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132dysfunction with reduced mortality was also demonstrated in
this study, which is consistent with previous ﬁndings (12).
Blecker et al. (14) appropriately detail several limitations
of their study, including the inability to identify physician
documentation of exceptions for not prescribing ACE
inhibitors/ARBs. The most noteworthy limitation, however,
is the use of the ARIC study methodology for identifying
heart failure patients (18), in which hospitalizations were
fully abstracted only if there was evidence of worsening
symptoms of heart failure or physician documentation of
heart failure as the reason for hospitalization. This not only
explains the high percentage (71%) of patients coded as
chronic stable heart failure who nonetheless had “acute
decompensated heart failure” but probably also results in
a major under-representation of patients with secondary
diagnoses of heart failure who had stable heart failure on
admission. Thus, the data as presented may be the tip of
the iceberg in terms of the percentage of patients with
secondary heart failure diagnoses who are not identiﬁed
and targeted appropriately for evidence-based therapies.
Hospitalizations are signal events that identify patients
with high mortality and morbidity rates over the subse-
quent few months. Whether heart failure is the primary or
secondary diagnosis, hospital admissions offer the opportu-
nity to identify and manage those conditions that contribute
to heart failure decompensation, such as ischemia, atrial
ﬁbrillation, and ventricular dyssynchrony.
Unfortunately, another real-world ﬁnding of Blecker et al.
(14) is the glaring underuse of ACE inhibitors/ARBs in
patients with LV systolic dysfunction, even in those with
a primary heart failure diagnosis, despite the high rate of
diagnostic testing to assess LV function. Although ACE
inhibitors/ARBs were given to more patients with a primary
(64%) than a secondary (56%) heart failure diagnosis, the
overall utilization of ACE inhibitors/ARBs was remar-
kably low. Given the signiﬁcant link between ACE inhib-
itor/ARB therapy and improved survival in this study,
consistent with multiple randomized clinical trials and
guidelines recommendations (11), the underperformance on
this measure represents an egregious gap in care that pro-
vides an unsettling wake-up call that ongoing monitor-
ing of heart failure quality metrics and attention to all
aspects of evaluation and treatment are necessary to achieve
optimal outcomes.
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